S-1 · primary offering
Issued 2024
Proposed maximum
Shares registered
- Filed
- Effective
MGX$0.7601+0.68%
Metagenomi Therapeutics, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$28.71M
Float & O/S:
Inst Own:
DilutionScan read 27 of Metagenomi Therapeutics, Inc.'s SEC filings and found 1 ATM program, 1 shelf registration and 1 S-1 registration on file for MGX. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Oct 7, 2026.
Signal8 Summary
Raise routes on file: active ATM + effective shelf · latest dilution event 126 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Jun 30, 2026 · ATM Sale
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Completed
ATM program
Issued 2025
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Know who's about to sell into your MGX trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
